ANI Pharmaceuticals (NASDAQ:ANIP) Stock: Insider Meredith Cook Sells 500 Shares

ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) VP Meredith Cook sold 500 shares of the business’s stock in a transaction on Friday, November 13th. The shares were sold at an average price of $70.80, for a total value of $35,400.00. Following the sale, the vice president owned 72,924 shares in the company, valued at approximately $5,163,019.20. The trade was a 0.68% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Meredith Cook also recently made the following trade(s):

• On Tuesday, October 13th, Meredith Cook sold 500 shares of ANI Pharmaceuticals stock. The stock was sold at an average price of $73.59, for a total value of $36,795.00.
• On Monday, September 14th, Meredith Cook sold 500 shares of ANI Pharmaceuticals stock. The stock was sold at an average price of $70.79, for a total value of $35,395.00.

ANI Pharmaceuticals Price Performance

NASDAQ ANIP traded up $0.38 during trading hours on Friday, hitting $71.44. The company had a trading volume of 383,853 shares, compared to its average volume of 474,006. ANI Pharmaceuticals, Inc. has a 52 week low of $67.14 and a 52 week high of $87.76. The firm has a 50 day simple moving average of $72.32 and a 200 day simple moving average of $77.00. The company has a debt-to-equity ratio of 0.92, a quick ratio of 2.33 and a current ratio of 2.75. The firm has a market capitalization of $1.62 billion, a price-to-earnings ratio of 14.23, a PEG ratio of 2.29 and a beta of 0.45.

ANI Pharmaceuticals (NASDAQ:ANIP) last announced its quarterly earnings results on Thursday, November 5th. The specialty pharmaceutical company reported $2.70 earnings per share for the quarter, beating the consensus estimate of $2.18 by $0.52. ANI Pharmaceuticals had a return on equity of 28.34% and a net margin of 11.22%. The firm had revenue of $290.78 million for the quarter, compared to analysts’ expectations of $280.59 million. During the same period in the prior year, the business posted $2.04 earnings per share. The company’s revenue was up 27.6% on a year-over-year basis. Equities research analysts expect that ANI Pharmaceuticals, Inc. will post 7.76 earnings per share for the current year.

Institutional Trading of ANI Pharmaceuticals

Several institutional investors and hedge funds have recently modified their holdings of the business. Hohimer Wealth Management LLC grew its position in ANI Pharmaceuticals by 4.1% in the third quarter. Hohimer Wealth Management LLC now owns 3,638 shares of the specialty pharmaceutical company’s stock worth $264,000 after acquiring an additional 142 shares in the last quarter. The Manufacturers Life Insurance Company increased its stake in ANI Pharmaceuticals by 1.5% in the first quarter. The Manufacturers Life Insurance Company now owns 9,577 shares of the specialty pharmaceutical company’s stock valued at $736,000 after acquiring an additional 143 shares during the last quarter. Commonwealth Equity Services LLC raised its position in ANI Pharmaceuticals by 5.0% during the third quarter. Commonwealth Equity Services LLC now owns 3,148 shares of the specialty pharmaceutical company’s stock valued at $229,000 after purchasing an additional 150 shares in the last quarter. Hantz Financial Services Inc. raised its position in ANI Pharmaceuticals by 24.7% during the third quarter. Hantz Financial Services Inc. now owns 778 shares of the specialty pharmaceutical company’s stock valued at $57,000 after purchasing an additional 154 shares in the last quarter. Finally, James Investment Research Inc. raised its position in ANI Pharmaceuticals by 4.3% during the third quarter. James Investment Research Inc. now owns 4,850 shares of the specialty pharmaceutical company’s stock valued at $352,000 after purchasing an additional 200 shares in the last quarter. Hedge funds and other institutional investors own 76.05% of the company’s stock.

Analysts Set New Price Targets

A number of analysts recently weighed in on the stock. Leerink Partners assumed coverage on shares of ANI Pharmaceuticals in a report on Wednesday, September 9th. They set an “outperform” rating and a $104.00 target price on the stock. Weiss Ratings reiterated a “hold (c+)” rating on shares of ANI Pharmaceuticals in a research note on Wednesday, November 4th. Wall Street Zen downgraded shares of ANI Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a report on Saturday, August 8th. Canaccord Genuity Group reduced their price target on shares of ANI Pharmaceuticals from $91.00 to $90.00 and set a “hold” rating for the company in a research report on Monday, August 10th. Finally, Oppenheimer assumed coverage on shares of ANI Pharmaceuticals in a research report on Wednesday, September 23rd. They set a “market perform” rating and a $85.00 price target for the company. Three analysts have rated the stock with a Buy rating and four have issued a Hold rating to the company’s stock. According to data from MarketBeat, the stock has an average rating of “Hold” and a consensus price target of $100.00.

About ANI Pharmaceuticals

ANI Pharmaceuticals, Inc. is a specialty pharmaceutical company that develops, manufactures and markets branded and generic prescription medicines. Its portfolio includes products in areas such as rare disease, specialty care and established brands, alongside a range of generic drugs. The company’s rare-disease portfolio includes Purified Cortrophin Gel, a prescription medicine used to treat certain inflammatory and other conditions. ANI also produces and markets complex and specialty generics, which can require more involved development or manufacturing than conventional generic drugs.